



# Borrok et al Supplemental figures

# Figure S1

A



B



C

	Sample	Mass	Height	% Total
Species 2	QRN Reduced	52018.51661	90852	6
	QRN Reduced	52179.31534	67022	5
	QRN Reduced	52287.99189	89912	6
	QRN Reduced	52448.54812	56721	4
	QRN Reduced	52400.91966	88382	6
	QRN Reduced	52562.56794	58933	4

	File	Mass	Height	% Total
Species 1	QRN Reduced	53528.37878	322869	22
	QRN Reduced	53690.50362	197587	13
	QRN Reduced	53625.74179	137540	9
	QRN Reduced	53786.51993	98286	7
	QRN Reduced	53738.17141	177519	12
	QRN Reduced	53900.55413	98620	7

	Total Height	%Total
Species 1	1032421	70
Species 2	451822	30

D

	Sample	Mass	Height	% Total
Species 2	QRNPRL (G0F)	51988.7012	11143	1
	QRNPRL (G1F)	52117.7456	51569	4
	QRNPRLRL (G0F)	52231.1261	39317	3
	QRNPRLRL (G1F)	52343.7297	70267	5
	QRNPRLRL (G0F)	52504.2771	25091	2
Species 1	KLKL Reduced	53470.8689	481850	36
	KLKL Reduced	53632.8522	205468	15
	KLKL Reduced	53566.671	144460	11
	KLKL Reduced	53727.9933	76197	6
	KLKL Reduced	53680.7203	187465	14
	KLKL Reduced	53842.8811	64536	5

	Total Height	%Total
Species 1	1159976	86
Species 2	197387	14

QRNPKL (G0F)  
QRNPKLK (G0F)  
QRNPKLKL (G0F)  
QRNPKLKL (G0F)  
QRNPKLKLIR (G0F)  
QRNPKLKLIR (G1F)  
QRNPRLRLIRRHPTLRIPI (G0F)  
QRNPRLRLIRRHPTLRIPI (G1F)

**Figure S1. LC-MS of purified Cam-003-QRN and Cam-003-KLKL antibodies.** Heavy Chain peaks identified after antibody reduction are shown for the QRN peptide fusion (A) and the KLKL fusion (B). Two major species are identified: Species 1 containing full length and 1 or 2 amino acid clipped species and Species 2 with cleavage occurring in the middle of the c-terminal peptide. Peak height was then used to estimate the relative abundance of either species 1 & 2 heavy chains for QRN (C) and KLKL (D) fused antibodies.

**Table S1.**

C-terminal Peptide Sequence	Reference	Monomer content upon purification	pIgR Binding
<b>SAMFVPPFDIAVGVRDGQQGL</b> GGSRRKGARLREAISSYAE	White KD & Capra JD 2002. J. Exp. Med. 196(4):551-5.	>95%	Slight
<b>VDDLTLQSRSPPSQLNSQHL</b> LLSQLCGYWMFRVRSRSCC G	White KD & Capra JD 2002. J. Exp. Med. 196(4):551-5.	60%	No
<b>IPSVTRMTVGGTLRKEFQDV</b> VLGVIFGLVLVINRCSFL	White KD & Capra JD 2002. J. Exp. Med. 196(4):551-5.	>95%	No
<b>CVVWMGFQQVC</b>	C9A peptide; Braathen R, <i>et al.</i> 2006 J. Biol. Chem. 281(11):7075-81.	60%	No
DDEATILADNKCMSTRVTSRII PSTEDPNEDIVERNIRIVVPLN NRENISDPTSPRLRRNFVYHLS DVSKKCDPVVELEDQVVTA TQSNICNEDDGVPETCYMYD RNKCYTTMVPRLRYHGETKMW QAALTPDSCYLD	Murine J chain	61%	No
QEDERIVLVVDNKCKSARITSRI IRSSEDPNEDIVERNIRIVVPLN NRENISDPTSPRLTRFVYHLS DLSKKCDPTEVELDNQIVTAT QSNICDEDSATETCYTYDRN KCYTAVVPLVYGGGETKMWET ALTPDACYPD	Human J chain	58%	No
<b>QRNPRLRLIRRHPTRLIPPI</b>	White KD & Capra JD 2002. J. Exp. Med. 196(4):551-5.	>95%	Yes
<b>QRNP<span style="font-weight: bold;">KLKLIRRHPTRLIPPI</span></b>	This study; QRN derivative	>95%	Yes

All peptides (or J-chains) were fused to the IgG heavy chain C-terminal with a GGGGS linker as a spacer. Amino acids in bold are the abbreviated peptide name.

**Table S2.**

Sequence	% Species 1 (full length) via MS	plgR binding
QRN <b>PRLRL</b> IIRRHPTLRIPI (original QRN)	70%	Yes
QRN <b>PRRRR</b> IIRRHPTLRIPI	<1%	No
QRN <b>PQRQ</b> IIRRHPTLRIPI	N.D.	No
QRN <b>PRKRK</b> IIRRHPTLRIPI	42%	Yes
QRN <b>PRPRP</b> IIRRHPTLRIPI	N.D.	No
QRN <b>PKLKL</b> IIRRHPTLRIPI	85%	Yes

Mutations in the 'RLRL' sequence of the QRN peptide were mutated and analyzed for plgR binding and percentage of 'full-length' peptide.

# Figure S2




Figure S2. Size exclusion Chromatography (SEC) traces of purified Cam-003-QRN and Cam-003-KLKL

# Figure S3




Figure S3. Opsonophagocytosis assay with luminescent *P. aeruginosa* serogroup 05 strain PAO1 (PAO1.lux) & baby rabbit complement show Cam-003-QRN (blue) and Cam-003-KLKL (green) having slightly decreased OPK activity compared to the parental molecule Cam-003 (black) (A). No OPK activity was observed for the isotype control IgG R347 (grey circle) or media alone (grey square). Data are representative of at least 2 independent experiments.